Capella BioScience Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
3
- Latest Deal Type
-
M&A
Capella BioScience General Information
Description
Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics for oncology and autoimmune disease, enabling researchers to research the latest medical technology-based drugs.
Contact Information
Website
www.capellabioscience.comCorporate Office
- 158-160 North Gower Street
- London NW1 2ND
- England, United Kingdom
Corporate Office
- 158-160 North Gower Street
- London NW1 2ND
- England, United Kingdom
Capella BioScience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 16-Feb-2021 | Completed | Clinical Trials - General | |||
| 4. Later Stage VC | 24-Sep-2020 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC | 16-Aug-2019 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 03-Apr-2016 | $15.7M | $18.1M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 22-Dec-2014 | $2.35M | $2.35M | Completed | Startup |
Capella BioScience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Shares | ||||||||
| Preference | ||||||||
| A Shares | 2,171,715 | $0.001306 | $2.59 | $2.59 | 1x | $2.59 | 1.73% | |
| Seed | 1,500,000 | $0.001306 | $1.31 | $1.31 | 1x | $1.31 | 17.12% |
Capella BioScience Comparisons
Industry
Financing
Details
Capella BioScience Competitors (15)
One of Capella BioScience’s 15 competitors is Galectin Therapeutics, a Corporation company based in Norcross, GA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Neogene Therapeutics | Formerly VC-backed | Santa Monica, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Akero Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Amunix Pharmaceuticals | Formerly PE-Backed | South San Francisco, CA |
Capella BioScience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Capella BioScience Patents
Capella BioScience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202000814-D0 | Antigen binding molecules that bind bdca-2 | Inactive | 20-Jan-2020 | ||
| GB-201911188-D0 | Antigen binding molecules that bind bdca-2 | Inactive | 05-Aug-2019 | ||
| CA-3147096-A1 | Anti bdca-2 antibodies | Pending | 05-Aug-2019 | ||
| AU-2020324542-A1 | Anti bdca-2 antibodies | Pending | 05-Aug-2019 | ||
| US-20220162322-A1 | Anti bdca-2 antibodies | Pending | 05-Aug-2019 | C07K16/2851 |
Capella BioScience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Capella BioScience Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advent Life Sciences | Venture Capital | Minority | ||
| DCVC | Venture Capital | Minority | ||
| Angel (individual) | Minority | |||
| Index Ventures | Venture Capital | Minority | ||
| Lux Capital | Venture Capital | Minority |
Capella BioScience FAQs
-
When was Capella BioScience founded?
Capella BioScience was founded in 2014.
-
Where is Capella BioScience headquartered?
Capella BioScience is headquartered in London, United Kingdom.
-
What is the size of Capella BioScience?
Capella BioScience has 3 total employees.
-
What industry is Capella BioScience in?
Capella BioScience’s primary industry is Drug Discovery.
-
Is Capella BioScience a private or public company?
Capella BioScience is a Private company.
-
What is Capella BioScience’s current revenue?
The current revenue for Capella BioScience is .
-
How much funding has Capella BioScience raised over time?
Capella BioScience has raised $37.7M.
-
Who are Capella BioScience’s investors?
Advent Life Sciences, DCVC, , Index Ventures, and Lux Capital are 5 of 7 investors who have invested in Capella BioScience.
-
Who are Capella BioScience’s competitors?
Galectin Therapeutics, Neogene Therapeutics, NexImmune, Akero Therapeutics, and Amunix Pharmaceuticals are some of the 15 competitors of Capella BioScience.
-
When was Capella BioScience acquired?
Capella BioScience was acquired on 16-Feb-2021.
-
Who acquired Capella BioScience?
Capella BioScience was acquired by Centessa Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
